

# APTUS PHARMA LIMITED

---

**Date: October 18, 2025**

To,  
The Manager,  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers, Dalal Street,  
Mumbai – 400001.

**Subject: Reply to clarification on price movement sought by BSE Limited**

**Reference: Email dated October 17, 2025 (Movement in Price Letter No. L / SUR / ONL / PV / AJ / 2025-2026 / 3154)**

**Scrip code: 544529**

We wish to clarify that the Company has consistently disclosed all material events and information that could affect its operations and performance, including price-sensitive information, in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. All such disclosures have been made to the Stock Exchange promptly and in compliance with applicable regulations.

To the best of our knowledge, the Company has not withheld any material information or events that could significantly impact the price movement of its securities. Should any information arise that requires disclosure under the aforementioned regulations, we will ensure it is communicated in a timely and appropriate manner.

We would like to emphasize that the recent price movement of the Company's securities is purely market-driven, and the management is in no way involved in or responsible for these fluctuations.

We trust this serves as a sufficient clarification in response to your letter and kindly request an acknowledgment of receipt.

**For, Aptus Pharma Limited**

---

**CS Mohini Hardik Gandhi**  
**Company Secretary and Compliance Officer**  
**M. No. A50437**

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM